Tebentafusp Doubles 5-Year Survival, but HLA-Negative Patients Still Wait
Tebentafusp reached 16% five-year survival vs 8% for investigator's choice, while darovasertib-crizotinib more than doubled PFS in HLA-A*02:01–negative metastatic uveal melanoma.